Toll-like receptor dependent innate immune responses by primary mouse hepatocytes and its control of HBV replication.
- Author:
Jun WU
1
;
Ming-fa CHEN
;
You-chen XIA
;
Yan GUO
;
Yong LIN
;
Chan SUN
;
Chun-yan ZHANG
;
Yan CHEN
;
Shen-pei LIU
;
You-hua HAO
;
Meng-ji LU
;
Jörg F SCHLAAK
;
Dong-liang YANG
Author Information
- Publication Type:Journal Article
- MeSH: Animals; Cells, Cultured; Hepatitis B virus; immunology; physiology; Hepatocytes; immunology; metabolism; Immunity, Innate; Mice; Mice, Inbred C57BL; Signal Transduction; Toll-Like Receptors; immunology; metabolism; Virus Replication
- From: Chinese Journal of Hepatology 2011;19(11):838-842
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVEThis report aims to investigate the Toll-like receptor (TLR) signaling pathways and induced antiviral activity in hepatocytes.
METHODSWe isolated primary hepatocytes from wild-type C57BL/6 mice and examined the expression of TLR by realtime RT-PCR. Hepatocytes were stimulated with TLR 1-9 agonists and the supernatants were harvested. The secretion of cytokines were tested by ELISA. The antiviral effectors in supernatants were assayed via virus protection assay (in EMCV system) and the control of HBV replication were assessed via Southern blotting (in HBV system).
RESULTSWe demonstrated that hepatocytes expressed TLR1-9. In accordance with these TLR expression profiles, hepatocytes responded to all TLR ligands by producing inflammatory cytokines (TNF-α or IL-6), to TLR -1,-3,-7 and -9 ligands by producing type I IFN (IFN-α or IFN-β). Only TLR 3 and TLR 7 agonists could stimulate the production of high amounts of antiviral mediators by hepatocytes in virus protection assay. By contrast, supernatants from TLR1, -3 and -4 directly stimulated hepatocytes and TLR 3, -7 and -9 transfected hepatocytes were able to potently suppress HBV replication.
CONCLUSIONPrimary hepatocytes display a unique TLR signaling pathway and can control HBV replication after stimulation by TLR agonists in mice. It may be helpful for the development of TLR-based therapeutic approaches against hepatotropic virus.